- Home
- SJT vs TARA Comparison
SJT vs TARA Comparison
Compare SJT & TARA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SJT | TARA |
|---|---|---|
| Founded | 1980 | N/A |
| Country | United States | United States |
| Employees | 495 | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.8M | 159.6M |
| IPO Year | N/A | 2014 |
Fundamental Metrics
Financial Performance| Metric | SJT | TARA |
|---|---|---|
| Price | $3.28 | $2.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $25.71 |
| AVG Volume (30 Days) | 376.1K | ★ 1.3M |
| Earning Date | 11-12-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 38.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,948,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.37 | $2.28 |
| 52 Week High | $6.55 | $7.82 |
Technical Indicators
Market Signals| Indicator | SJT | TARA |
|---|---|---|
| Relative Strength Index (RSI) | 41.30 | 38.18 |
| Support Level | $2.68 | $2.28 |
| Resistance Level | $3.27 | $2.83 |
| Average True Range (ATR) | 0.30 | 0.16 |
| MACD | -0.09 | 0.05 |
| Stochastic Oscillator | 7.55 | 35.45 |
Price Performance
Historical ComparisonAbout SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About TARA Protara Therapeutics Inc.
Protara Therapeutics Inc is a clinical-stage biopharmaceutical company focused on advancing its therapies for the treatment of cancer and rare diseases. Its drug development pipeline includes: TARA-002, an investigational cell therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs); and IV Choline Chloride, an investigational phospholipid substrate replacement therapy, for patients receiving parenteral support, or PS, which includes both nutrition and fluids.